Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

DUPRO steering committee and PROTECT Investigators

21 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science